These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20431446)

  • 41. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
    Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
    Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center.
    Watt K; Uhanova J; Minuk GY
    Am J Gastroenterol; 2002 Aug; 97(8):2046-50. PubMed ID: 12190175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
    Gülberg V; Gerbes AL
    Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
    Møller S; Bendtsen F; Henriksen JH
    Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatorenal syndrome: pathogenesis and novel pharmacological targets.
    Barada K
    Curr Opin Pharmacol; 2004 Apr; 4(2):189-97. PubMed ID: 15063365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt.
    Spahr L; Fenyves D; N'Guyen VV; Roy L; Legault L; Dufresne MP; Pomier-Layrargues G
    Am J Gastroenterol; 1995 Jul; 90(7):1169-71. PubMed ID: 7611221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatorenal syndrome: emerging perspectives.
    Epstein M
    Semin Nephrol; 1997 Nov; 17(6):563-75. PubMed ID: 9353866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatorenal syndrome.
    Guevara M; Rodés J
    Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome.
    Morrow JD; Moore KP; Awad JA; Ravenscraft MD; Marini G; Badr KF; Williams R; Roberts LJ
    J Lipid Mediat; 1993; 6(1-3):417-20. PubMed ID: 8358000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The hepatorenal syndrome.
    Munoz SJ
    Med Clin North Am; 2008 Jul; 92(4):813-37, viii-ix. PubMed ID: 18570944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatorenal syndrome: definition, pathophysiology, clinical features and management.
    Bataller R; Sort P; Ginès P; Arroyo V
    Kidney Int Suppl; 1998 May; 66():S47-53. PubMed ID: 9573573
    [No Abstract]   [Full Text] [Related]  

  • 54. [Hepatorenal syndrome].
    Lautrette A; Liotier J; Deteix P; Souweine B
    Nephrol Ther; 2009 Apr; 5(2):150-6. PubMed ID: 18514053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Scenarios in Acute Kidney Injury: Hepatorenal Syndrome.
    Meola M; Nalesso F; Petrucci I; Samoni S; Ronco C
    Contrib Nephrol; 2016; 188():33-8. PubMed ID: 27169751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatorenal syndrome and type 1 and 2 cardiorenal syndromes: distinct competing medical therapies applied to a similar background of vasomotor reactive nephropathy.
    De Vecchis R; Esposito C; Di Biase G; Ariano C
    Minerva Cardioangiol; 2014 Feb; 62(1):105-16. PubMed ID: 24500221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New clues to the pathophysiology of hepatorenal failure.
    Lang F; Gerok W; Häussinger D
    Clin Investig; 1993 Feb; 71(2):93-7. PubMed ID: 8461632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiology of the hepatorenal syndrome and potential for therapy.
    Levy M
    Am J Cardiol; 1987 Dec; 60(17):66I-72I. PubMed ID: 3687808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Splanchnic vasodilation and renal vasoconstriction: a key to the hepatorenal syndrome?
    Bosch J
    Hepatology; 1990 Dec; 12(6):1445-7. PubMed ID: 2258162
    [No Abstract]   [Full Text] [Related]  

  • 60. Reply. When to stop non-selective beta-blockers: the window hypothesis in clinical practice.
    Krag A; Gluud LL
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):458. PubMed ID: 25532009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.